Evofem Biosciences, Inc. (EVFM)

Market Cap	3.22M
Revenue (ttm)	13.56M
Net Income (ttm)	46.76M
Shares Out	215.96M
EPS (ttm)	-1.24
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	740,620
Open	0.0125
Previous Close	0.0128
Day's Range	0.0125 - 0.0155
52-Week Range	0.0120 - 3.7500
Beta	-1.16
Analysts	Hold
Price Target	n/a
Earnings Date	Aug 29, 2023

About EVFM

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women; and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Ms. Saundra Pelletier
• Employees: 37
• Stock Exchange: OTCMKTS
• Ticker Symbol: EVFM

Financial Performance

In 2022, EVFM's revenue was $16.84 million, an increase of 104.23% compared to the previous year's $8.24 million. Losses were -$76.70 million, -62.62% less than in 2021.